Copyright © 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
Editor-in-Chief: Natalia Ortúzar
Impact Factor: 3.046
ISI Journal Citation Reports © Ranking: 2013: 18/58 (Chemistry Medicinal); 74/254 (Pharmacology & Pharmacy)
Online ISSN: 1860-7187
August 28, 2014
C. A. Olsen interview at ChemistryViews
ChemMedChem author and this year's recipient of the EFMC Prize for a Young Medicinal Chemist in Academia, Professor Christian A. Olsen (University of Copenhagen), recently answered some questions we had about the work behind his paper Effect of Various Zinc Binding Groups on Inhibition of Histone Deacetylases 1–11, which appeared earlier this year in our Special Issue on Epigenetics and Drug Discovery. He also discussed his research projects and goals in general, and what makes his successful research group tick. The full interview can be found at ChemistryViews. Be sure to catch Olsen's Concept article, also in the Epigenetics special issue.
Recently Published Articles
- You have free access to this content
- The Importance of Hydration Thermodynamics in Fragment-to-Lead Optimization
Dr. Osamu Ichihara, Yuzo Shimada and Daisuke Yoshidome
Article first published online: 27 AUG 2014 | DOI: 10.1002/cmdc.201402207
Solving solvation: Using a computational approach, we investigated the effects of water molecules on the binding energetics of over 20 fragment hit/lead pairs taken from real drug discovery programs. The analysis reveals a distinct difference between the thermodynamic profile of the water molecules displaced by fragment hits and those displaced by the optimized leads.
- Biological Evaluation of Potent Triclosan-Derived Inhibitors of the Enoyl–Acyl Carrier Protein Reductase InhA in Drug-Sensitive and Drug-Resistant Strains of Mycobacterium tuberculosis
Dr. Jozef Stec, Dr. Catherine Vilchèze, Dr. Shichun Lun, Dr. Alexander L. Perryman, Xin Wang, Prof. Joel S. Freundlich, Prof. William Bishai, Prof. William R. Jacobs Jr. and Prof. Alan P. Kozikowski
Article first published online: 27 AUG 2014 | DOI: 10.1002/cmdc.201402255
Antimycobacterial activity was sought for novel triclosan (TRC) analogues obtained through structural modifications at positions 5 and 4′ of the diaryl ether scaffold. Among 27 analogues tested, several molecules were highly active against drug-susceptible and drug- resistant strains of M. tuberculosis, with the 4-(n-butyl)-1,2,3-triazolyl TRC derivative (3) being identified as one of the most potent TRC derivatives reported to date. Further biochemical investigations of the most promising compounds supported inhibition of InhA as the likely mechanism of action.
- 5-(Piperidin-4-yl)-3-Hydroxypyrazole: A Novel Scaffold for Probing the Orthosteric γ-Aminobutyric Acid Type A Receptor Binding Site
Dr. Jacob Krall, Dr. Kenneth T. Kongstad, Birgitte Nielsen, Troels E. Sørensen, Dr. Thomas Balle, Dr. Anders A. Jensen and Dr. Bente Frølund
Article first published online: 26 AUG 2014 | DOI: 10.1002/cmdc.201402248
Exploring hydrophobic cavities in the vicinity of the GABAAR binding site leads to novel antagonists. Increasing the hydrophobicity of the N1- or N2-substituents of a new GABAA receptor antagonist scaffold results in a similar SAR between the compound series. However, docking studies suggest different binding modes for the two series in the GABAA receptor binding site.
- Molecular Mechanism of Action of 2-Ferrocenyl-1,1-diphenylbut-1-ene on HL-60 Leukemia Cells
Dr. Alane Cabral de Oliveira, Emanuella Gomes da Silva, Dr. Danilo Damasceno Rocha, Dr. Elizabeth A. Hillard, Dr. Pascal Pigeon, Prof. Gérard Jaouen, Felipe A. R. Rodrigues, Prof. Fabiane C. de Abreu, Dr. Fabrícia da Rocha Ferreira, Prof. Marilia O. F. Goulart and Prof. Letícia V. Costa-Lotufo
Article first published online: 25 AUG 2014 | DOI: 10.1002/cmdc.201402219
Who is the ferrous one of all? 2-Ferrocenyl-1,1-diphenylbut-1-ene, a ferrocene–tamoxifen derivative, provokes DNA fragmentation and apoptosis in HL-60 cells, but is inactive against noncancerous cells. These results suggest that this ferrocene hybridization strategy may have utility in the future design of antineoplastic therapeutics.